InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2024-05-29 00:00:00 ET · period of report 2024-05-28 · accession 0001104659-24-066045 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-29 2024-05-28 REGN BROWN MICHAEL S Dir M - OptEx $625.60 +1,172 2,554 +85% +$733.2K
D 2024-05-29 2024-05-28 REGN BROWN MICHAEL S Dir S - Sale+OE $974.86 -1,172 1,382 -46% -$1.14M
D 2024-05-29 2024-05-28 REGN BROWN MICHAEL S Dir M - OptEx $0.00 -1,172 1,535 -43% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-28 M A 1,172 $625.60 2,554 D — —
2 Common Common Stock 2024-05-28 S D 1,172 $974.86 1,382 D — —
3 Derivative Non-Qualified Stock Option (right to buy) 2024-05-28 M D 1,172 $0.00 1,535 D $625.60 · — to 2032-01-03 1,172 Common Stock (F3) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.